CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 59.8%

Gross margin was 59.8% in Q1 FY2026, down 40.2 pp from a year earlier. On a trailing-twelve-month basis it was 76.2%, up 30.8 pp year over year.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.8%-40.2 pp QoQ
Last fiscal yearDec 2025
53.1%-46.9 pp YoY
LTMMar 2026
76.2%+30.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-40.2 pp——
1 year-46.9 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
53.1%
Year-over-year change
-46.9pp

Gross Margin vs competitors

How CAMP compares with its peers on the latest reported figures

  • CAMP's LTM Mar 2026 gross margin of 76.2% is the 2nd highest of the 4 companies compared; the peer median is 60.3%.
  • Its year-over-year change of +30.8 pp is the highest of 3, against a peer median of +5.4 pp.
CAMP Competitors Peer median
Gross Margin for CAMP and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 2026100.0% +0.0 pp+0.0 pp
CAMPCAMP4 Therapeutics CorporationLTM Mar 202676.2% +30.8 pp—
HYFTMindWalk Holdings Corp.LTM Jan 202660.3% +10.9 pp-1.5 pp
ATYRaTyr Pharma, Inc.LTM Mar 2026-11754.7% —-801.0 pp
ALXOALX Oncology Holdings Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding CAMP) 60.3%+5.4 pp-1.5 pp

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.